Free tool
FAERS Monitor: Istodax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022393 or its brand name (Istodax, Romidepsin). Reports on generic versions are filed under their own applications.
Reports
1,689
Serious
1,456
86% of reports
Hospitalization
569
Death reported
447
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death126
- nausea124
- thrombocytopenia120
- peripheral t-cell lymphoma unspecified118
- pyrexia105
- drug ineffective91
- anaemia80
- fatigue80
- vomiting78
- platelet count decreased74
- electrocardiogram qt prolonged71
- disease progression66
- product storage error64
- neutropenia63
- atrial fibrillation61
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 39 |
| 2011 | 48 |
| 2012 | 67 |
| 2013 | 83 |
| 2014 | 74 |
| 2015 | 129 |
| 2016 | 128 |
| 2017 | 76 |
| 2018 | 124 |
| 2019 | 186 |
| 2020 | 132 |
| 2021 | 108 |
| 2022 | 174 |
| 2023 | 68 |
| 2024 | 113 |
| 2025 | 87 |
| 2026 | 53 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,470 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| peripheral t-cell lymphoma unspecifiedSignal | 118 | 3096.4 | 2545.6 | 290,018 |
| electrocardiogram qt prolongedSignal | 71 | 24.6 | 19.6 | 1,586 |
| thrombocytopeniaSignal | 120 | 13.4 | 11.3 | 1,368 |
| product storage errorSignal | 64 | 9.1 | 7.2 | 456 |
| platelet count decreasedSignal | 74 | 8.7 | 6.9 | 495 |
| atrial fibrillationSignal | 61 | 7.8 | 6.1 | 357 |
| disease progressionSignal | 66 | 6.9 | 5.5 | 332 |
| neutropeniaSignal | 63 | 5.8 | 4.5 | 245 |
| anaemiaSignal | 80 | 5.2 | 4.2 | 271 |
| pyrexiaSignal | 105 | 3.8 | 3.1 | 215 |
| vomitingSignal | 78 | 2.1 | 1.7 | 43 |
| nausea | 124 | 2.0 | 1.6 | 59 |
| death | 126 | 1.8 | 1.5 | 48 |
| fatigue | 80 | 1.3 | 1.0 | 5 |
| drug ineffective | 91 | 0.9 | 0.7 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.